Literature DB >> 15580194

Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome.

Aaron L Carrel1, Victoria Moerchen, Susan E Myers, M Tracy Bekx, Barbara Y Whitman, David B Allen.   

Abstract

OBJECTIVES: To determine the effect of growth hormone (GH) on body composition and motor development in infants and toddlers with Prader-Willi syndrome (PWS). STUDY
DESIGN: Twenty-nine subjects with PWS (4-37 months of age) were randomized to GH treatment (1mg/m 2 /day) or observation for 12 months. Percent body fat, lean body mass, and bone mineral density were measured by dual x-ray absorptiometry; energy expenditure was measured by deuterium dilution; and motor constructs of mobility (M) and stability (S) were assessed using the Toddler Infant Motor Evaluation (TIME).
RESULTS: GH-treated subjects, compared with controls, demonstrated decreased percent body fat (mean, 22.6% +/- 8.9% vs 28.5% +/- 7.9%; P < .001), increased lean body mass (mean, 9.82 +/- 1.9 kg vs 6.3 +/- 1.9 kg; P < .001), and increased height velocity Z scores (mean, 5. 0 +/- 1.8 vs 1.4 +/- 1.0; P < .001). Patients who began GH before 18 months of age showed higher mobility skill acquisition compared with controls within the same age range (mean increase in raw score, 284 +/- 105 vs 206 +/- 63; P < .05).
CONCLUSIONS: GH treatment of infants and toddlers with PWS for 12 months significantly improves body composition and when begun before 18 months of age increases mobility skill acquisition. These results suggest that GH therapy instituted early in life may lessen deterioration of body composition in PWS while also accelerating motor development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15580194     DOI: 10.1016/j.jpeds.2004.08.002

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  33 in total

1.  Guest editor: P.S.N. Menon - Editorial: childhood and adolescence growth and growth disorders.

Authors:  P S N Menon
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

2.  Human growth hormone therapy in Prader-Willi syndrome.

Authors: 
Journal:  Paediatr Child Health       Date:  2005-04       Impact factor: 2.253

Review 3.  Pharmacotherapy in pediatric obesity: current agents and future directions.

Authors:  Abigail B Wald; Naveen K Uli
Journal:  Rev Endocr Metab Disord       Date:  2009-09       Impact factor: 6.514

4.  Contributing factors of mortality in Prader-Willi syndrome.

Authors:  Jennifer Proffitt; Kathryn Osann; Barbara McManus; Virginia E Kimonis; Janalee Heinemann; Merlin G Butler; David A Stevenson; June-Anne Gold
Journal:  Am J Med Genet A       Date:  2018-12-19       Impact factor: 2.802

5.  Effects of growth hormone treatment in adults with Prader-Willi syndrome.

Authors:  M G Butler; B K Smith; J Lee; C Gibson; C Schmoll; W V Moore; J E Donnelly
Journal:  Growth Horm IGF Res       Date:  2013-02-19       Impact factor: 2.372

6.  Endocrine problems in children with Prader-Willi syndrome: special review on associated genetic aspects and early growth hormone treatment.

Authors:  Dong-Kyu Jin
Journal:  Korean J Pediatr       Date:  2012-07-17

7.  Growth charts for non-growth hormone treated Prader-Willi syndrome.

Authors:  Merlin G Butler; Jaehoon Lee; Ann M Manzardo; June-Anne Gold; Jennifer L Miller; Virginia Kimonis; Daniel J Driscoll
Journal:  Pediatrics       Date:  2014-12-08       Impact factor: 7.124

8.  Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.

Authors:  L A Gondoni; L Vismara; P Marzullo; R Vettor; A Liuzzi; G Grugni
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

9.  Respiratory Depression in Young Prader Willi Syndrome Patients following Clonidine Provocation for Growth Hormone Secretion Testing.

Authors:  Gregory A Hollman; David B Allen; Jens C Eickhoff; Aaron L Carrel
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-28

10.  Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin).

Authors:  Dana S Hardin
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.